Takeda Pharmaceutical Company Limited (TAK) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for joining us for FY25Q1 earnings announcement by Takeda, despite your very busy schedule today. I'm the master of the ceremony, head of AYA. My name is O'Reilly. Thank you for this opportunity. And I would like to explain about the language setting to begin with. Please find the language selection button at the bottom of your Zoom window. If you wish to listen in Japanese, please select the Japanese channel. If English, please choose the English channel. And if you want to listen to the original, please turn it off. For those of you who wish to listen to this call in English, please select English in the Zoom language select button. 本日のコールでは米国の1995年 Before starting, I'd like to remind everyone that we'll be discussing forward-looking statements with the meaning of the Private Securities Litigation Reforms Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20F and in our other SEC findings. Please also refer to the important notice on page two of the presentation regarding forward-looking statements, non-IFRS financial measures, which will also be discussed during this call. Definitions of non-IFRS measures and reconciliations with the comparable IFRS financial results are included in the appendix to the presentation. Now we would like to begin. Presentation will be given by Christophe Weber, President and CEO, Milano Fruta, Chief Financial Officer, and Andy Plump, R&D President. And this will be followed by Q&A session. Let us begin. Thank you, Chris, and thank you everyone for joining us today. Our fiscal year 2025 first quarter results reflect the significant impact of Vivant's generic erosion on revenue incorporating pro...